Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Celsius Holdings

Cintas Corp

Rollins

Celsius brings triple-digit sales growth with newfound profitability. Cintas and Rollins are home to products you don't know you love until you don't have them.

4 Magnificent Stocks I'm Done Waiting on a Dip for in 2024 -- but I'm Not Buying Them Hand Over Fist, Either

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) has been selected as a 2024 Catalyst Award recipient for its global initiative, Awareness and Action Drives Impact, that is advancing equity for women and other underrepresented groups across the company — from the frontlines to senior leadership. Zoetis is one of only two organizations receiving this global award and is the first animal health company to be recognized. “We are truly honored to receive the 2024 Catalyst Award for our glo.

Zoetis Wins 2024 Catalyst Award

ORLANDO, Fla.--(BUSINESS WIRE)--The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony. Andrea J. Gonzales Ph.D., vice president of Global Companion Animal Therapeutics at Zoetis, Inc., (NYSE: ZTS) was awarded the 2024 Feather in Her Cap award and Katharina Bohnenblust Ph.D., senior director, head of Formulation Development at Elanco Animal Health (NYSE.

2024 Feather in Her Cap and High Flyer Award Winners Named for Outstanding Achievements in Animal Health Industry

Grifols, S.A.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Zoetis Inc. is a leading veterinarian healthcare provider with a focus on companion animals and the cattle industry. The company projects sustained growth through innovative products and strategic investments, targeting a 3-point premium market growth. Zoetis is well-positioned to outperform with a strong financial outlook, a diversified portfolio, and the increasing prioritization of pet health.

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Cigna

Elevance Health Inc

Humana

Incyte

Insulet

UnitedHealth Group

Health Care Select Sector SPDR Fund

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024

Domino's Pizza

EOG Resources

Mastercard

Microchip Technology

MarketAxess Holdings

MSCI

NIKE

Sirius XM Holdings Inc

SPDR S&P 500 ETF Trust

SS&C Technologies Hlds

Texas Instruments

Visa

Vanguard Dividend Appreciation ETF

Essential Utilities

The SPDR S&P 500 ETF was up 4.57% in December, Vanguard's Dividend Appreciation ETF was up 4.13%, and my watchlist beat both with a return of 9.52%.

My Top 15 High Growth Dividend Stocks For January 2024

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 13, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/eve.

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2023 Financial Results

Chewy

Freshpet

Pet care stocks are incredibly effective in diversifying investment portfolios, leveraging the robust growth of the pet care industry. The sector's expansion is evident.

Pet Care Profits: 3 Stocks Benefitting from the Pet Boom

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 3:45 p.m. PT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation.

Zoetis to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

ABM Industries

Clorox

Kenvue

Lam Research

NextEra Energy

York Water

Some investments just look after themselves. They are “set it and forget it” kind of stocks.

Forever Favorites: 7 Dividend Stocks to Buy and Never Sell

Assurant

Ares Management

Broadcom

Deere & Company

Comfort Systems USA

Intuit

JPMorgan Chase & Co

Lennox International

Martin Marietta Materials

Microsoft

NRG Energy

Old Dominion Freight Line

Parker-Hannifin

PulteGroup

Wingstop

We focus on selecting high-growth dividend stocks that have rapidly grown their dividends in the recent past rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. We provide criteria for selecting high-growth dividend stocks and offer a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Dividend Growth Stocks - December 2023

Choice Hotels Int.

Invitation Homes

Owens Corning

Invitation Homes Inc. (INVH), Choice Hotels International, Inc. (CHH), Zoetis Inc. (ZTS) and Owens Corning (OC) recently announced dividend hikes.

4 Stocks to Watch That Recently Declared Dividend Hikes

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the first quarter of 2024, an increase of 15% from the quarterly dividend rate paid in 2023. The dividend will be paid on Friday, March 1, 2024, to all holders of record of the Company's common stock as of the close of business on Friday, January 19, 2024. “Zoetis has continued to perform well this year thanks to our diverse and innovative product portfolio,” said.

Zoetis Declares First Quarter 2024 Dividend; Board Approves 15% Payment Increase

PetMed Express

Pet stocks are an exciting way to diversify your portfolio. These companies ride high on the tailwinds of the pet care industry, which took many analysts by surprise.

3 Promising Stocks to Buy in the Booming Pet Tech Industry

Amgen

Stryker

The company offers integrated products and value-added services for Account holders Merchants Financial institutions Businesses Governments Mastercard also provides value-added products and services comprising cyber and intelligence solutions for parties to transact and proprietary insights, drawing on the moral use of consumer and merchant data services.

5 Sizzling Wall Street ‘Strong Buy” Stocks Are Also Raising Their Dividends This Week

Bank of America

Discover

Charles Schwab

Tractor Supply

The SPDR S&P 500 ETF was up 9.13% in November, Vanguard's Dividend Appreciation ETF was up 7.47%, my watchlist beat both with a return of 10.24%. The top 15 dividend growth stocks for December offer an average dividend yield of 1.99% and appear to be about 34% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is rocking a cool 11.76% annualized return, beating VIG by 2.36% and SPY by 1.52%.

My Top 15 High Growth Dividend Stocks For December 2023

Most recent data shows that 66% of U.S. households own a pet. Another interesting point is that “85% of dog owners and 76% of cat owners consider their pets to be a member of the family.

3 Pet Care Stocks to Capitalize on the Animal Economy

News for Zoetis Stock (ZTS)